The offering is the key catalyst; its success determines whether Eloxx can fund its Phase 2b Alport syndrome and Phase 2 ADPKD trials. Monitor for pricing, Nasdaq approval, and trial initiation in Q3 2026. The reverse stock split and pending uplisting are critical structural events for share liquidity.
Executive Summary
Eloxx Pharmaceuticals filed Amendment No. 2 to its S-1 registration statement for a public offering of 2,730,000 shares of common stock and pre-funded warrants to purchase up to 2,770,000 shares of common stock at an assumed price of $10.00-$12.00 per share. The company estimates net proceeds of approximately $54.2 million, which it plans to use to fund its Phase 2b trial of exaluren in Alport syndrome (topline data mid-2027) and a Phase 2 trial in ADPKD (topline data mid-2028). The offering is contingent upon Nasdaq uplisting approval; the company currently trades on the OTC Pink Limited Market.
Key Financial Metrics
Key Facts
- Offering 2,730,000 shares of common stock and pre-funded warrants to purchase up to 2,770,000 shares of common stock at assumed $10.00-$12.00 per share.
- Estimated net proceeds of approximately $54.2 million, based on the midpoint of the price range.
- Plans to use $13.2 million for exaluren Phase 2b trial in Alport syndrome through topline data and $19.2 million for exaluren Phase 2 trial in ADPKD through completion.
- Company has a going concern qualification and an accumulated deficit of $304.3 million as of March 31, 2026.
- Offering is contingent upon Nasdaq Capital Market approval; common stock currently quoted on OTC Pink Limited Market.
- Net losses of $6.0 million (FY2025), $3.1 million (FY2024), and $3.8 million (Q1 2026).
- Cash and cash equivalents of $6.4 million as of March 31, 2026; pro forma cash of $60.6 million after offering.
Financial Impact
Estimated net proceeds of ~$54.2 million from the offering, intended to fund clinical trials through mid-2028.
Risk Factors
- Substantial doubt about going concern if offering fails; company does not have funds to commence planned Phase 2 trials without proceeds.
- Delisting risk from OTC Pink; Nasdaq uplisting is a condition of the offering and not guaranteed.
- Clinical risk: FSD has not been validated as a surrogate endpoint for FDA approval in Alport syndrome.
- Material weakness in internal controls over financial reporting has not been remediated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001193125-26-257750 |
| Document: d35071dex1060.htm | 0001193125-26-257750 |
| Document: d35071dexfilingfees.htm | 0001193125-26-257750 |
| Document: d35071dex231.htm | 0001193125-26-257750 |
| Document: 0001193125-26-257750-index-headers.html | 0001193125-26-257750 |
| Document: 0001193125-26-257750-index.html | 0001193125-26-257750 |
| Document: 0001193125-26-257750.txt | 0001193125-26-257750 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | 8-K | $13.12 | awaiting T+20 | — | $12.99 (−0.99%) |
Sep 21, 2026 5w ago | EFFECT | $17.19 $12.50 | ▼ −27.28% | ▼ −26.38% | $12.99 (−24.43%) |
Sep 11, 2026 6w ago | S-1 | $16.30 | awaiting T+20 | — | $12.99 (−20.31%) |
Jun 9, 2026 19w ago | EFFECT | $11.01 $10.95 | ▼ −0.55% | ▼ −1.99% | $12.99 (+17.98%) |
Jun 4, 2026 20w ago | S-1/A | $6.20 | awaiting T+20 | — | $12.99 (+109.52%) |
Jun 1, 2026 20w ago | S-1/A | $1.51 | awaiting T+20 | — | $12.99 (+760.26%) |
Jun 1, 2026 21w ago | 8-K | $4.07 $13.88 | ▲ +241.03% | ▲ +242.33% | $12.99 (+219.16%) |
May 7, 2026 24w ago | S-1 | $1.43 | awaiting T+20 | — | $12.99 (+807.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers